PARP1 and urinary bladder cancer: Carboplatin is an alkylating agent known to induce PARP activity and is potentiated by PARP inhibition in preclinical models,22, 35 and the carboplatin/paclitaxel doublet is a well‐tolerated regimen with activity across multiple solid tumor types including ovarian,36 head and neck,37 non‐small cell lung,38 esophageal,39 breast,40 and bladder cancers.37, 41